Abstract: The following generally relates to using image classification techniques to determine the acceptability of form documents. In some examples, an image classification model may be trained to apply a first label to form documents that are acceptable and a second label to form documents that are unacceptable. In these examples, the image classification model may include a neural network, such as a convolutional neural network. Accordingly, the systems and methods generally relate to obtaining a submitted form document, inputting the submitted form document into the trained image classification model, and/or enforcing the acceptability decision of the image classification model.

Abstract: Embodiments disclosed are directed to a computing system that performs steps to perform enhanced device fingerprinting using user contacts data. The computing system receives, from an application, a first plurality of device attributes identifying a client device on which the application is being used. The first plurality of device attributes includes first device identification data and first user contacts data. Subsequently, when a user is attempting to perform a transaction using the application on the client device, the computing system receives, from the application, a second plurality of device attributes identifying the client device on which the application is being used. The second plurality of device attributes includes second device identification data and second user contacts data. The computing system compares the second plurality of device attributes to the first plurality of device attributes to determine whether the user is authorized to perform the transaction.

Abstract: Disclosed herein are stability-enhanced formulations that comprise a therapeutic protein and a stability-improving amount of a stabilizing excipient, wherein the stabilized-enhanced formulation is characterized by an improved stability parameter in comparison to a control formulation otherwise identical to the stability-enhanced formulation but lacking the stabilizing excipient. Further disclosed herein are methods of improving stability of therapeutic formulations or improving parameters of protein-related processes.

Abstract: The invention encompasses formulations and methods for the production thereof that permit the delivery of concentrated protein solutions. The inventive methods can yield a lower viscosity liquid protein formulation or a higher concentration of therapeutic or nontherapeutic proteins in the liquid formulation, as compared to traditional protein solutions. The inventive methods can also yield a higher stability of a liquid protein formulation.

Abstract: A method for determining authenticity of a document in real-time is disclosed. The method being performed by a processor includes receiving image data of a document. The image data corresponds to at least two images of the document taken simultaneously using at least two cameras. The method includes analyzing the image data to determine a plurality of measurements corresponding to the document along three dimensions. The method includes a thickness at a plurality of location points on the document based on the plurality of measurements, and determining authenticity of the document in real-time based on the determined thickness of the document at the plurality of location points.

Abstract: Disclosed herein are reduced viscosity liquid formulations comprising a protein and an excipient compounds. Further disclosed are methods of reducing the viscosity of a liquid formulation comprising a protein, methods of treatment, and methods of improving protein processing.

Abstract: Disclosed herein are formulations with improved stability or reduced viscosity that comprise a therapeutic protein and a lyo-enhancing excipient, wherein the improved stability formulation is characterized by improved stability in comparison to a control formulation otherwise identical to the stability-enhanced formulation but lacking the lyo-enhancing excipient, and the reduced viscosity formulation is characterized by reduced viscosity in comparison to a control formulation otherwise identical to the reduced viscosity formulation but lacking the lyo-enhancing excipient. Further disclosed herein are methods of improving stability of therapeutic formulations, reducing viscosity of therapeutic formulations, or improving parameters of lyophilization processes.

Abstract: Embodiments disclosed are directed to a computing system that performs steps to perform enhanced device fingerprinting using user contacts data. The computing system receives, from an application, a first plurality of device attributes identifying a client device on which the application is being used. The first plurality of device attributes includes first device identification data and first user contacts data. Subsequently, when a user is attempting to perform a transaction using the application on the client device, the computing system receives, from the application, a second plurality of device attributes identifying the client device on which the application is being used. The second plurality of device attributes includes second device identification data and second user contacts data. The computing system compares the second plurality of device attributes to the first plurality of device attributes to determine whether the user is authorized to perform the transaction.

Abstract: Disclosed herein are stability-enhanced formulations that comprise a therapeutic protein and a stability-improving amount of a stabilizing excipient, wherein the stabilized-enhanced formulation is characterized by an improved stability parameter in comparison to a control formulation otherwise identical to the stability-enhanced formulation but lacking the stabilizing excipient. Further disclosed herein are methods of improving stability of therapeutic formulations or improving parameters of protein-related processes.

Abstract: Disclosed herein are stability-enhanced formulations that comprise a therapeutic protein and a stability-improving amount of a stabilizing excipient, wherein the stabilized-enhanced formulation is characterized by an improved stability parameter in comparison to a control formulation otherwise identical to the stability-enhanced formulation but lacking the stabilizing excipient. Further disclosed herein are methods of improving stability of therapeutic formulations or improving parameters of protein-related processes.

Abstract: A method for etching a barrier material on a semiconductor substrate is disclosed. The method includes placing the substrate in a plasma processing chamber of the plasma processing system, wherein the substrate includes the barrier material and a low-k material, and wherein the barrier material and a low-k material are configured to be exposed to a plasma. The method also includes flowing an etchant gas mixture, including CH3F from about 4% to about 8% of a plasma gas flow, into the plasma processing chamber, wherein the etchant gas mixture is configured to etch the barrier material at a first etch rate, the etchant gas mixture is configured to etch the low-k material at a second etch rate, wherein the first etch rate is substantially greater than the second etch rate. The method further includes striking a plasma from the etchant source gas; and etching the barrier layer and the low-k layer.